Safety surveillance depends on reports that can be acted on
Medical-device safety monitoring can only work as well as the reports that reach regulators. A study published in The BMJ concludes that summary adverse-event reports submitted to the US Food and Drug Administration frequently contain gaps that can make it harder to identify potential safety problems quickly.
US manufacturers are generally required to report device malfunctions and adverse events to the FDA’s Manufacturer and User Facility Device Experience database, known as MAUDE. Those reports are a central part of post-market surveillance: they can inform safety measures, including recalls, after devices have entered routine use.
The researchers focused on a less transparent part of that system: summary reporting. Under previous and continuing exemptions, some manufacturers have been allowed to group adverse events into bulk submissions instead of filing reports for each individual case. The stated rationale has been to reduce the reporting burden on industry. But the study argues that the resulting data quality problems pose a public-health concern.
What the researchers examined
The analysis covered all adverse-event summary reports submitted to MAUDE over six years, from July 2019 through June 2025. The team assessed whether reports adequately identified device or use problems, accurately counted events, were properly labelled as summary reports, and met the FDA’s reporting deadlines for serious events.
In total, the researchers identified 6,308 summary reports containing 159,503 adverse events. Most concerned high-risk devices. The scale matters because high-risk devices are used in circumstances where reliable safety signals may be particularly consequential.
The findings point to recurring issues rather than isolated filing mistakes. Fifty-seven percent of the summary reports identified no device or use problem. Thirty-eight percent said there was insufficient information. Eleven percent were incorrectly identified as non-summary reports, while 7% listed one event in the field meant to state the number of events. More than half—55%—were filed after the FDA’s 30-day reporting deadline.
Why summary reporting is under scrutiny
MAUDE is intended to support the detection of emerging problems after a device reaches the market. A report that lacks a clear account of what went wrong, or that arrives late, is less useful for spotting patterns across patients, products or clinical settings. Bulk reporting can further complicate that task when the underlying events are not individually visible in the same way as standard filings.
The FDA ended its Alternative Summary Reporting program in 2019 after concerns that the system could obscure safety signals. Yet the study notes that similar summary-reporting exemptions remain in use. Their accuracy, completeness and compliance with reporting rules had not been clearly established, providing the impetus for the new analysis.
The researchers do not present adverse-event reports as a perfect record of device performance. Passive reporting systems have inherent limits, and the source data may itself be incomplete. Their point is narrower and more immediate: a surveillance system that relies on submitted information needs those submissions to be timely, accurately classified and specific enough to be assessed.
The policy question
The study’s authors call for immediate improvements to protect patients and meet FDA reporting standards. The findings raise practical questions for regulators and manufacturers alike. If summary reporting is retained, the data need to consistently show what happened, how many events occurred and whether a serious incident was reported on time.
For regulators, the challenge is balancing administrative efficiency with the ability to detect meaningful patterns. For manufacturers, post-market reporting is not simply a compliance exercise; it is part of the information pipeline used to identify whether a product may require closer review or action.
The study also arrives as reporting volumes continue to grow, adding pressure to systems designed to turn filings into safety intelligence. Better data fields and clearer classification would not eliminate the limits of passive surveillance. They could, however, reduce avoidable blind spots in a process meant to surface warning signs before they become larger patient-safety problems.
What comes next
The central conclusion is that the quality of summary reports deserves more scrutiny. The researchers found missed deadlines, unclear problem descriptions and errors in how submissions were counted and labelled across a substantial number of filings. Those weaknesses can delay or complicate the detection of potential risks.
As medical devices become more complex and more widely deployed, post-market oversight will remain essential. The study makes the case that reporting exemptions should not become exceptions to the basic requirements of completeness, accuracy and promptness. In a safety-monitoring system built around early signals, those details are the signal.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
